Evogene Q4 2023 Earnings Report

Evogene EPS Results

• Actual EPS: -$1.30
• Consensus EPS: -$1.40
• Beat/Miss: Beat by +$0.10
• One Year Ago EPS: -$0.70

Evogene Revenue Results

• Actual Revenue: $0.58 million
• Expected Revenue: $1.73 million
• Beat/Miss: Missed by -$1.15 million
• YoY Revenue Growth: N/A

Evogene Announcement Details

• Quarter: Q4 2023
• Date: 3/7/2024
• Time: Before Market Opens

Evogene (NASDAQ:EVGN), together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.